Paper - WANFANG MED ONLINE

You Position: Home > Paper

Expert consensus on clinical application of new anti-tuberculosis drug bedaquoline (2020 update)

( views:823, downloads:1217 )

Author:: No author available

Journal Title:: Chinese Journal of Tuberculosis and Respiratory Diseases

Issue:: 2

DOI:: 10.3760/cma.j.cn112147-20200714-00805

Key Word:: No keyword available

Abstract：贝达喹啉（bedaquiline）被世界卫生组织列为耐利福平结核病（RR-TB）和耐多药结核病（MDRTB）长程治疗方案的首选药物。2018年，中华医学会结核病学分会组织专家撰写了“抗结核新药贝达喹啉临床应用专家共识”，为贝达喹啉在我国的临床应用提供了重要的指导。近2年来，国内外贝达喹啉临床与基础方面的研究取得了新进展。为进一步合理有效使用该药，中华医学会结核病学分会根据最新的国内外文献及指南，对“抗结核新药贝达喹啉临床应用专家共识”进行了更新。本共识内容包括贝达喹啉的分子结构和抗结核分枝杆菌的作用机制、贝达喹啉的药效学研究、贝达喹啉的药物代谢动力学研究、贝达喹啉的临床研究、贝达喹啉临床应用推荐等5个方面，以供我国结核病防治工作者借鉴与参考。

Reference

[1]中华医学会结核病学分会,抗结核新药贝达喹啉临床应用专家共识编写组.抗结核新药贝达喹啉临床应用专家共识[J].2018,(6).
[2]中华医学会结核病学分会.中国耐多药和利福平耐药结核病治疗专家共识（2019年版）[J].2019,(10).
[3]Andries, Koen,Verhasselt, Peter,Guillemont, Jerome,etc.A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis.[J].2005,307(5707).
[4]Cantarero L,Andries K,Lenaerts AJ,etc.Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.[J].2007,51(9).
[5]Max R,O'Donnell,Nesri,Padayatchi,Amrita,Daftary,etc.Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection.[J].2019,6(3).
[6].Drug resistance mechanisms and novel drug targets for tuberculosis therapy[J].2017,44(1).
[7]Guglielmetti, Lorenzo,Jaspard, Marie,Le Du, Damien,etc.Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis[J].2017,49(3).
[8].In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug -resistant tuberculosis from Beijing, China.[J].2017,(Spec).
[9]Donald PR,Allen J,Reddy C,etc.Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis.[J].2008,52(8).
[10]Zimenkov, Danila V.,Nosova, Elena Yu.,Kulagina, Elena V.,etc.Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region[J].2017,72(7).
[11]Diacon,A.H.,Pym,A.,Grobusch,M.P.,etc.Multidrug-resistant tuberculosis and culture conversion with bedaquiline[J].2014,371(8).
[12]Huitric E,Verhasselt P,Koul.Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor.[J].2010,54(3).
[13]Ghajavand, Hasan,Kamakoli, Mansour Kargarpour,Khanipour, Sharareh,etc.High Prevalence of Bedaquiline Resistance in Treatment-Naive Tuberculosis Patients and Verapamil Effectiveness[J].2019,63(3).
[14]唐神结,李亮,高文等.中国结核病年鉴(2018)[M].2019.
[15]Emanuele Pontali,Mario C. Raviglione,"ORCID":"http:\/\/orcid.org\/0000-0002-2597-574XGiovanni Battista Migliori.Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives[J].2019,28(152).
[16]Vergauwen K,Ristic Z,Vranckx L,etc.Diarylquinolines target subunit c of mycobacterial ATP synthase[J].2007,3(6).
[17]Andries, Koen,Villellas, Cristina,Coeck, Nele,etc.Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline.[J].2014,9(7).
[18]Tasneen R,Nuermberger EL,Andries K,etc.Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.[J].2011,55(12).
[19]Nazir A, Ismail,Shaheed V, Omar,Lavania, Joseph,etc.Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study.[J].2018,(Spec ).
[20]Matteelli A,Carvalho AC,Dooley KE,etc.TMC207: the first compound of a new class of potent anti-tuberculosis drugs.[J].2010,5(6).
[21]Hartkoorn,R.C.,Uplekar,S.,Cole,S.T..Cross-resistance between clofazimine and bedaquiline through upregulation of mmpl5 in mycobacterium tuberculosis[J].2014,58(5).
[22]Andries K,Veziris N,Ibrahim M,etc.A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.[J].2009,179(1).
[23]Veziris N,Andries K,Lounis N,etc.Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.[J].2007,51(3).
[24]Xu, Jian,Wang, Bin,Hu, Minghao,etc.Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis[J].2017,61(6).
[25]Conradie, Francesca,Dannemann, Brian,Pym, Alexander S.,etc.Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis[J].2016,47(2).
[26]Koul A,Van den Wyngaert I,Vergauwen K,etc.Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis[J].2008,283(37).
[27]Almeida, Deepak,Ioerger, Thomas,Tyagi, Sandeep,etc.Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis[J].2016,60(8).
[28]Gilissen,R.,Rouan,M.-C.,Andries,K.,etc.Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis[J].2012,56(3).
[29]唐神结,李亮,高文等.中国结核病年鉴(2017)[M].2018.
[30]Karen Cohen,Gary Maartens.A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis[J].2019,18(10).
[31]Matthias I Gr?schel,James A Seddon,Satria A Prabowo,etc.European guidance on drug-resistant tuberculosis in children and adolescents[J].2020,4(1).
[32]Andries K,Hoffner SE,Huitric E,etc.In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor.[J].2007,51(11).
[33]Koul, Anil,Vranckx, Luc,Dhar, Neeraj,etc.Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism[J].2014,5(Feb.).
[34]Ismail, N.,Omar, S., V,Ismail, N. A.,etc.In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants[J].2018,153.
[35]De Marez T,Patientia R,Palomino JC,etc.The diarylquinoline TMC207 for multidrug-resistant tuberculosis.[J].2009,360(23).
[36]Andries K,Dhillon J,Phillips PP,etc.Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells.[J].2010,90(5).
[37]Guglielmetti, Lorenzo.Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity?[J].2017,49(5).